Shilpa Medicare shares rise 5% as European Medicines Agency greenlights blood-clot, heart attack treatment drug

At around 11:24 am, the stock was trading 2.65% higher at ₹840.10 per equity share.

This comes after the Karnataka-headquartered firm received the initial authorisation from the European Medicines Agency (EMA), recommending the grant for a final marketing approval for its Rivaroxaban 10 mg, 15 mg, and 20 mg orodispersible films (ODF), a drug used for the treatment of blood clotting, heart attacks, and strokes, it said in a regulatory filing on Monday.

The medicine is a bioequivalent and available as a generic form of Bayer’s Xarelto, which is available as oral tablets. It “is the only Rivaroxaban in ODF form which can help in patient comfort, especially in geriatric patients (60 years or older),” Shilpa Medicare added.

The company said the drug is an anticoagulant medicine, which means it's used to treat blood clotting. Furthermore, it is used in the treatment of deep vein thrombosis and pulmonary embolism, and to prevent their recurrence in adults. It is also used to prevent atherothrombotic events (such as heart attack, stroke, or death from heart disease) in adults, Shilpa Medicare added.

The approval was granted for the firm’s US FDA, Europe, and MHRA UK-approved manufacturing facility in Bengaluru. It marks the facility’s third approval for a prescription oral mouth dissolving film product in the European market.

The total European market for oral Rivaroxaban formulations is about $2.5 billion, the filing stated.

Shilpa Medicare stock performance

The share gained 1.83% over the week but lost 1.42% over a period of three months. However, it surged 26.17% over a period of six months. On a year-to-date basis, it has advanced 2.61%.

While the scrip reached a 52-week high of ₹1,000 on June 16, 2025, it touched a year’s low of ₹555 apiece on April 7, 2025.

Shilpa Medicare has a total market capitalisation of ₹8,222.75 crore, as of September 23, 2025, according to data on the NSE.